VETOLEXIN 250 PASTE

Country: Canada

Language: English

Source: Health Canada

Active ingredient:

CEPHALEXIN (CEPHALEXIN MONOHYDRATE)

Available from:

VETOQUINOL N A INC

Dosage:

250MG

Pharmaceutical form:

PASTE

Composition:

CEPHALEXIN (CEPHALEXIN MONOHYDRATE) 250MG

Administration route:

ORAL

Units in package:

6X15ML SYR

Prescription type:

Prescription

Therapeutic group:

DOGS

Product summary:

Active ingredient group (AIG) number: 0105911004

Authorization status:

CANCELLED POST MARKET

Authorization date:

2018-02-08

Patient Information leaflet

VETOQUINOL N.-A. INC.
Commercial Division
2000, CHEMIN GEORGES, LAVALTRIE, QC, J5T 3S5
Telephone:
450-586-2252
Order Desk: 800-363-1700
Fax:
450-586-4649
Website:
www.vetoquinol.ca
Email:
[e-mail]
Every effort has been made to ensure the accuracy of the information
published. However, it remains the responsibility of the
readers to familiarize themselves with the product information
contained on the Canada product label or package insert.
VETOLEXIN
®
VÉTOQUINOL
Cephalexin Oral Paste
VETERINARY USE ONLY
Meat flavour
PR
VETOLEXIN 100
DIN 02353911
ACTIVE INGREDIENTS: Each mL of paste contains 100 mg Cephalexin (as
monohydrate) in a triglyceride base.
PR
VETOLEXIN 250
DIN 02353938
ACTIVE INGREDIENTS: Each mL of paste contains 250 mg Cephalexin (as
monohydrate) in a triglyceride base.
INDICATION
Antibiotic for the treatment of canine superficial pyoderma caused by
susceptible strains of
Staphylococcus intermedius.
Note: It is recommended to obtain samples for in vitro culture and
susceptibility testing prior to treatment. When this is not
practical, culture and susceptibility results after initiation of
VETOLEXIN therapy should be reviewed to confirm susceptibility
of the pathogens.
DOSAGE AND ADMINISTRATION
Administer orally 25 mg/kg every 8 to 12 hours for 2 to 4 weeks.
VETOLEXIN can be given with or without food. Administer
directly into the dogs mouth or onto its food.
The determination of a dosage regimen for any particular patient
should take into consideration factors such as the
severity and the nature of the infection, susceptibility of the
causative organisms, clinical experience and the integrity of the
host-defence mechanisms. When treating dogs with superficial pyoderma,
it is recommended to continue treatment for
7 days beyond a clinical cure. If no clinical improvement is seen
after 3-5 days of treatment, therapy should be
discontinued and the case re-evaluated.
HOW TO USE THE DIAL-A-DOSE SYRINGE
1. Hold the syringe with the tip pointing upward (make sure the cap is
still secured) and the ma